Phase 3 N=37 Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Levels of Fluocinolone Acetonide in Plasma and Aqueous Humor — 1.4905; 0.7140 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=945 The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
Status Asthmaticus
Primary: Patients Hospitalization Rate — 82; 75 participants
Phase 3 N=1,791 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Type 2 Diabetes Mellitus
Primary: Primary Major Macrovascular Events — 264; 235 participants — p=<0.05
Phase 3 N=193 Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 28 Days of Blinded Treatment — 1.459; 1.465 Liters
Phase 3 N=1,547 MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001
Phase 3 N=258 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -11.3; -5.3 scores on a scale — p=<0.001
Phase 3 N=99 A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -22.6; -15.4 scores on a scale
Phase 3 N=59 A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -18.3 scores on a scale
Phase 3 N=739 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants
Phase 3 N=207 A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by…
Phase 3 N=83 A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Hemophilia A
Primary: Annualized Number of All Bleeds — 57.7; 4.9 Bleeds per year per participant — p=0.0001
Phase 3 N=590 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome With Constipation
Primary: Overall Responder Rate — 13.8; 7.8 percentage of participants — p=0.029
Phase 3 N=607 Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Change From Baseline in MADRS Total Score After 8 Weeks of Treatment. — -11.70; -17.23; -18.79; -21.15 units on a scale — p=<0.0001
Phase 3 N=366 Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Epilepsies, Partial
Primary: PCH(T), ITT — -42.90; -38.20; -28.70 percentage of change — p==0.003
Phase 3 N=182 Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by…